UBS Group’s Psyence Biomedical PBM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.8K Buy
330
+270
+450% +$1.1K ﹤0.01% 10164
2026
Q2
$184 Buy
+60
New +$273 ﹤0.01% 10017
2026
Q1
– Sell
-161
Closed -$758 – 11284
2025
Q4
$758 Buy
+161
New +$2.4K ﹤0.01% 9824
2025
Q3
– Sell
-313
Closed -$10.4K – 11046
2025
Q2
$10.4K Sell
313
-361
-54% -$10K ﹤0.01% 8840
2025
Q1
$20.1K Buy
674
+419
+164% +$26.7K ﹤0.01% 8236
2024
Q4
$26.8K Buy
255
+251
+6,275% +$59.8K ﹤0.01% 7686
2024
Q3
$1.5K Sell
4
-2
-33% -$2.71K ﹤0.01% 8621
2024
Q2
$6.87K Buy
6
+5
+500% +$15K ﹤0.01% 7882
2024
Q1
$2.7K Buy
+1
New +$4.17K ﹤0.01% 7846

Other funds holding PBM

UBS Group's PBM Position: Q3 2026 in Review

UBS Group increased its Psyence Biomedical (PBM) stake by 450% in Q3 2026, buying an estimated $1.1K and bringing the position to 330 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #10164.

UBS Group first reported a position in PBM in Q1 2024 and has held it in 9 quarters since. The position peaked at $26.8K in Q4 2024. 10 funds tracked by Wall St. Rank hold PBM as of Q3 2026.

  • UBS Group held 330 shares of Psyence Biomedical worth $1.8K as of Q3 2026.
  • UBS Group bought 270 Psyence Biomedical shares in Q3 2026, an estimated $1.1K.
  • Psyence Biomedical made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10164 holding.
  • UBS Group first reported a position in Psyence Biomedical in Q1 2024 and has held it in 9 quarters since.
  • UBS Group's Psyence Biomedical position peaked at $26.8K in Q4 2024.
  • 10 funds tracked by Wall St. Rank held Psyence Biomedical as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.